Prospective, multi-center, randomized (1:1), controlled trial of Impella for active left ventricular unloading on top of veno-arterial extracorporeal membrane oxygenation vs. veno-arterial extracorporeal membrane oxygenation alone for the treatment of cardiogenic shock.
In the past years extensive efforts in developing treatment strategies for patients with cardiogenic shock have been performed. One promising such strategy is active unloading of the left ventricle while simultaneously supporting the circulatory system with veno-arterial extracorporeal membrane oxygenation. Recently, in a multinational, multicenter, retrospective registry, it has been shown that this approach might be associated with lower mortality . The investigators now seek to extend the evidence on this topic and to test this approach in a prospective, randomized, controlled, multicenter trial. A power calculation has been conducted based on the data from the registry. N=198 patients with cardiogenic shock will be randomized 1:1 to be either treated with an Impella for active left ventricular unloading on top of veno-arterial extracorporeal membrane oxygenation or with veno-arterial extracorporeal membrane oxygenation alone. A blinded interim analysis will be performed, which might lead to an adjustment of the enrollment target. The primary endpoint of this study will be death from any cause 30 days after randomization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
198
University Heart and Vascular Center Hamburg
Hamburg, Germany
RECRUITINGTime to death from any-cause within 30 days after randomization
Time to death from any-cause within 30 days after randomization
Time frame: 30 days
Death from any-cause at 6 and 12 months as well as time to death at these time points
Cardiovascular death at day 30, 6 months and 12 months as well as time to death at these time points
Time frame: 6 and 12 months
Cardiovascular death at day 30, 6 months and 12 months as well as time to death at these time points
Cardiovascular death at day 30, 6 months and 12 months as well as time to death at these time points
Time frame: 30 days, 6 and 12 months
Length of veno-arterial extracorporeal membrane oxygenation therapy, mechanical ventilation, inotrope therapy and stay at the intensive care unit (in days).
Length of veno-arterial extracorporeal membrane oxygenation therapy, mechanical ventilation, inotrope therapy and stay at the intensive care unit (in days).
Time frame: 12 months
Days free from veno-arterial extracorporeal membrane oxygenation therapy in 30 days
Days free from veno-arterial extracorporeal membrane oxygenation therapy in 30 days
Time frame: 30 days
Need for renal replacement therapy until day 30, 6 months and 12 months
Need for renal replacement therapy, intermittent or ongoing, until day 30, 6 months and 12 months
Time frame: 30 days, 6 and 12 months
Neurological function (per Cerebral Performance Category) at day 30, 6 months and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurological function (per Cerebral Performance Category) at day 30, 6 months and 12 months
Time frame: 30 days, 6 and 12 months
Rate of incidence of hospitalization for heart failure (hospitalization for more than 24 hours with heart failure as the main reason) as well as time to first event after 6 months and 12 months and recurrent events within 12 months
Rate of incidence of hospitalization for heart failure (hospitalization for more than 24 hours with heart failure as the main reason) as well as time to first event after 6 months and 12 months and recurrent events within 12 months
Time frame: 6 and 12 months
Left ventricular function assessed by echocardiography at day 30, 6 months and 12 months
Left ventricular function assessed by echocardiography at day 30, 6 months and 12 months
Time frame: 30 days, 6 and 12 months
Quality of life as assessed by the "Kansas City Cardiomyopathy Questionnaire" at 30-days and at 12 months
Quality of life as assessed by the "Kansas City Cardiomyopathy Questionnaire" at 30-days and at 12 months
Time frame: 30 days and 6 months
6-Minute Walking Distance at day 30, 6 months and 12 months
6-Minute Walking Distance at day 30, 6 months and 12 months
Time frame: 30 days, 6 and 12 months